Michael Smith, MD
Pulmonary Disease · Cleveland, OHNPI 1801329248
Payments from drug & device makers
Across 12 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$50
- Regeneron Healthcare Solutions, Inc.$43
- Sanofi$36
- Actelion Pharmaceuticals US, Inc.$32
- Atricure, Inc.$28
- Jazz Pharmaceuticals Inc.$28
- plus $58 from 3 others
What the payments were for
- Food & beverage$277100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Sanofi | 1 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Atricure, Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Grifols USA, LLC | 1 | $25 |
| Merck | 1 | $21 |
| Ambu Inc. | 1 | $13 |
How this compares
$277 in reported general payments places this provider in the 25th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $24,663 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $2,799 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $1,815 |
| Mycophenolate Mofetil | 13 | $979 |
| Hydroxychloroquine Sulfate | 26 | $588 |
| Azithromycin | 18 | $477 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $469 |
| Prednisone | 55 | $319 |
| Montelukast Sodium | 12 | $107 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $27 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Cleveland
- Kristin HighlandCleveland$3.2M
- Leslie TolleCleveland$1M
- Rodney FolzCleveland$733K
- Marie BudevCleveland$658K
- Joseph ParambilCleveland$586K
- Douglas ConradCleveland$461K
- Daniel CulverCleveland$456K
- Elliott DasenbrookCleveland$456K
- Michael MachuzakCleveland$390K
- Gustavo Heresi DavilaCleveland$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.